Bristol Myers Squibb: acquires Mirati Therapeutics
(CercleFinance.com) - Bristol Myers Squibb announces that it has entered into a definitive agreement to acquire the oncology biotech company Mirati Therapeutics, for $58 per share, representing a total equity value of $4.
8bn.
Mirati shareholders will also receive a non-negotiable conditional value right (CVR) for each Mirati share held, that is potentially worth $12 per share, representing an additional value opportunity of $1bn.
Thanks to this acquisition, Bristol Myers Squibb will strengthen its portfolio with Krazati, a US FDA-approved non-small cell lung cancer drug, as well as several other promising clinical assets.
The transaction is expected to have a non-GAAP dilutive effect of approximately $0.35 per share in the first 12 months following completion, which is expected by H1 2024, subject to customary conditions and regulatory approvals.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
8bn.
Mirati shareholders will also receive a non-negotiable conditional value right (CVR) for each Mirati share held, that is potentially worth $12 per share, representing an additional value opportunity of $1bn.
Thanks to this acquisition, Bristol Myers Squibb will strengthen its portfolio with Krazati, a US FDA-approved non-small cell lung cancer drug, as well as several other promising clinical assets.
The transaction is expected to have a non-GAAP dilutive effect of approximately $0.35 per share in the first 12 months following completion, which is expected by H1 2024, subject to customary conditions and regulatory approvals.
Copyright (c) 2023 CercleFinance.com. All rights reserved.